Indian stocks: Visit www.stage2stocks.com →

ProMIS Neurosciences Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, ProMIS Neurosciences is in Stage 4, the downtrend phase, now in week 2 (since Oct 13, 2026). It closed at $8.98, 63.8% below its 52-week high and below its 200-day average, which is rising.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. More about the company

$8.98
-1.64% today
$80.5M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PMN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 23w
S4 51w
S4 19w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 23w → S1 12w → S3 1w → S2 2w → S3 7w → S4 3w → S3 1w → S2 1w → S1 1w → S4 51w → S1 8w → S4 19w → S1 4w → S2 8w → S3 4w → S4 6w → S1 3w → S2 8w → S3 2w → S4 1w current
Total tracked: 165 weeks across 20 stage runs.

PMN among Biotechnology241st of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…241PMNStage 4 · wk 240−30.6%
vs 52W High
-63.8%
$6.76 lo$24.79 hi
63.8% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 2
1w13w26w
Week 2, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-30.3%
200 DMA: $12.88 · rising
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.19x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-30.6%
3M
-26.4%
6M
-17.5%
YTD
+25.8%
1Y
-18.4%
Scan Membership
Breakout Watch
Latest: 2024-07-29
8 appearances in last 60 days. First seen: 2019-03-29.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 2 · Vol 0.19x
2026-10-21S4
Wk 2 · Vol 0.18x
2026-10-20S4
Wk 2 · Vol 0.87x
2026-10-19S4
Wk 1 · Vol 0.32x
2026-10-16S4
Wk 1 · Vol 0.58x
2026-10-15S4
Wk 1 · Vol 0.95x
2026-10-14S4
Wk 1 · Vol 0.67x
2026-10-13S43→4
Wk 1 · Vol 0.77x
2026-10-12S3
Wk 2 · Vol 0.67x
2026-10-09S3
Wk 2 · Vol 0.53x
2026-10-08S3
Wk 2 · Vol 0.88x
2026-10-07S3
Wk 2 · Vol 0.33x
Moving averages & range
50 DMA
$12.00
200 DMA
$12.88
52W High
$24.79
52W Low
$6.76
5D Low
$8.09
Resistance levels (recent highs)
20d High
$11.27
60d High
$15.36
120d High
$15.36
250d High
$24.79
Next resistance
+25.5%
to 20d High
ROE
-172.3%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.6

ProMIS Neurosciences: quick answers

What stage is ProMIS Neurosciences in?

As of Oct 22, 2026, ProMIS Neurosciences (PMN) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 13, 2026 and is in week 2. What the four stages mean

Is ProMIS Neurosciences in an uptrend?

No. ProMIS Neurosciences is in a Stage 4 downtrend. It trades 30.3% below its 200-day average, which is rising.

How far is ProMIS Neurosciences from its 52-week high?

ProMIS Neurosciences closed at $8.98 on Oct 22, 2026, 63.8% below its 52-week high of $24.79. Its 52-week low is $6.76.

How has ProMIS Neurosciences performed over the past year?

As of Oct 22, 2026, ProMIS Neurosciences is down 18.4% over the past year and up 25.8% so far in 2026.

Which sector and industry is ProMIS Neurosciences in?

ProMIS Neurosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.